Skip to main content
QUIT logo

QUIT · Achieve Life Sciences, Inc. · Webcasts, Transcripts & Audio

Track QUIT — free
$5.73 -0.15 (-2.47%) Play latest call Q1 2026 earnings call transcript
Market Cap
$645.90M
Shares
110.03M
Volume · Nov 20 693.7K Avg daily vol (3M) 1.37M

Achieve Life Sciences, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Achieve Life Sciences, Inc. (QUIT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q2
2026-08-11
Achieve Life Sciences, Inc. (QUIT) Q2 2026 Earnings Call
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-07-02
Achieve Life Sciences, Inc. (QUIT) July 2, 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Achieve Life Sciences, Inc. (QUIT) Q1 2026 Earnings Call Transcript
Confident tone Competitive Landscape in Smoking Cessation Unmet Need and Public Health Opportunity Commercial Launch Preparation
Diluted EPS
$-0.19
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Achieve Life Sciences, Inc. (QUIT) Q4 2025 Earnings Call Transcript
Confident tone NDA submission and FDA progress Cytisinicline commercial launch preparation Unmet medical need in nicotine dependence
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Achieve Life Sciences, Inc. (QUIT) Q3 2025 Earnings Call Transcript
Confident tone Cytisinicline efficacy and clinical data Regulatory milestones and PDUFA Commissioner's National Priority Voucher (CNPV) for vaping
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Achieve Life Sciences, Inc. (QUIT) Q2 2025 Earnings Call Transcript
Confident tone Commercial launch planning and Omnicom partnership Cytisinicline clinical and safety profile NDA submission and regulatory progress
Diluted EPS
$-0.37
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Achieve Life Sciences, Inc. (QUIT) Q1 2025 Earnings Call Transcript
Confident tone NDA Submission Progress Cytisinicline Clinical Profile Market Opportunity and Unmet Need
Diluted EPS
$-0.37
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Achieve Life Sciences, Inc. (QUIT) Q4 2024 Earnings Call Transcript
Confident tone NDA submission for cytisinicline (smoking cessation) Market opportunity / unmet need in nicotine dependence Vaping cessation indication (ORCA-V2)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Achieve Life Sciences, Inc. (QUIT) Q3 2024 Earnings Call Transcript
Confident tone Cytisinicline Product Profile and Market Opportunity NDA Submission and Regulatory Progress Vaping Phase 3 Trial (ORCA-V2)
Diluted EPS
$-0.36
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Achieve Life Sciences, Inc. (QUIT) Q2 2024 Earnings Call Transcript
Confident tone Cytisinicline Regulatory Progress Vaping Cessation Indication Clinical Trial Enrollment
Diluted EPS
$-0.25
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Achieve Life Sciences, Inc. (QUIT) Q1 2024 Earnings Call Transcript
Confident tone ORCA-OL long-term safety trial initiation and enrollment NDA submission timeline and FDA agreement Vaping cessation and label expansion opportunity
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Achieve Life Sciences, Inc. (QUIT) Q4 2023 Earnings Call Transcript
Confident tone Clinical efficacy of cytisinicline FDA agreement and NDA path forward ORCA-OL long-term safety trial
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Achieve Life Sciences, Inc. (QUIT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.34
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Achieve Life Sciences, Inc. (QUIT) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.43
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Achieve Life Sciences, Inc. (QUIT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Achieve Life Sciences, Inc. (QUIT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Achieve Life Sciences, Inc. (QUIT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Achieve Life Sciences, Inc. (QUIT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.08
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Achieve Life Sciences, Inc. (QUIT) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Achieve Life Sciences, Inc. (QUIT) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Achieve Life Sciences, Inc. (QUIT) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.71
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Achieve Life Sciences, Inc. (QUIT) Q2 2021 Earnings Call Transcript
Diluted EPS
$-1.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Achieve Life Sciences, Inc. (QUIT) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Achieve Life Sciences, Inc. (QUIT) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Achieve Life Sciences, Inc. (QUIT) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Achieve Life Sciences, Inc. (QUIT) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Achieve Life Sciences, Inc. (QUIT) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Achieve Life Sciences, Inc. (QUIT) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 949858 13F (30d) 142 filings 123 filers Visit website Investor relations